🇺🇸 FDA
Pipeline program

rHuPH20

HZ2-08-02

Phase 1 small_molecule completed

Quick answer

rHuPH20 for Risk Factors for or a Diagnosis of Osteoporosis is a Phase 1 program (small_molecule) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
HALOZYME THERAPEUTICS, INC.
Indication
Risk Factors for or a Diagnosis of Osteoporosis
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials